Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 5/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | HTT | P42858 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | AKT1 | P31749 | 3/20 | 0.38 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.37 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.37 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.37 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 2/20 | 0.36 |
| ▸ | CA9 | Q16790 | 2/20 | 0.36 |
| ▸ | CA12 | O43570 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5697287 | 0.81 | LPL (0.38) | HSD17B10 | |
| SCHEMBL27878821 | 0.79 | IDO1 (0.46) | LMNA | |
| SCHEMBL7216900 | 0.78 | CA2 (0.69) | CA2SMN1; SMN2LMNAHTTTSHR | |
| SCHEMBL30765766 | 0.77 | DUT (0.40) | CA2SMN1; SMN2PTGS2CA1CA9 | |
| SCHEMBL30765819 | 0.77 | SLC6A4 (0.35) | CA2LMNAPTGS2PTGS1CA1 | |
| SCHEMBL14018319 | 0.77 | CA2 (0.70) | CA2SMN1; SMN2LMNAHTTAKT1 | |
| SCHEMBL12204115 | 0.75 | CA2 (0.68) | CA2SMN1; SMN2LMNAHTTAKT1 | |
| SCHEMBL20883032 | 0.75 | CA2 (0.68) | CA2SMN1; SMN2LMNAHTTAKT1 | |
| SCHEMBL22792207 | 0.75 | CA2 (0.68) | CA2SMN1; SMN2LMNAHTTAKT1 | |
| SCHEMBL12040857 | 0.75 | CA2 (0.68) | CA2SMN1; SMN2LMNAHTTAKT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4568666-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | Alexion Pharmaceuticals, Inc. (US) | 2025-06-18 | — | — | EP | disclosed |
| WO-2024035686-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ALEXION PHARMACEUTICALS, INC. (US) | 2024-02-15 | — | — | WO | disclosed |